ArticleOncotarget2022

Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning.

Ignacio Durán et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.